Neuro Pathophysiology PPT Flashcards
DSM-5 Criteria to diagnose dementia:
* Significant _____ decline from the ______ level
of performance in one or more cognitive domains
* Interferes with _____
* Does not occur exclusively in the context of a
delirium
* Not better explained by any other ______ or _________ condition
DSM-5 Criteria to diagnose dementia:
* Significant cognitive decline from the baseline level
of performance in one or more cognitive domains
* Interferes with the activities of daily living
* Does not occur exclusively in the context of a
delirium
* Not better explained by any other medical or
psychiatric condition
DSM-5 Criteria for delirium:
* Disturbance in _____ & _______
* Develops ______ and tends to ______
in severity.
* At least one additional disturbance in
cognition
* Not better explained by _______ ________
* Do not occur in the context of a
severely reduced level of arousal or
coma
* Evidence of an ______ _________
DSM-5 Criteria for delirium:
* Disturbance in attention & awareness
* Develops acutely and tends to fluctuate
in severity.
* At least one additional disturbance in
cognition
* Not better explained by preexisting
dementia.
* Do not occur in the context of a
severely reduced level of arousal or
coma
* Evidence of an underlying organic
cause or causes
Pathophysiology of Major Neurocognitive Disorder:
Accumulation of native _____ in the brain
(except vascular)
Pathophysiology of Major Neurocognitive Disorder:
Accumulation of native proteins in the brain
(except vascular)
Vascular dementia ~____% of all dementia cases
* Incidence increases with ___
* Doubles every _____ years
* Risk factors (4):
Vascular dementia ~15% of all dementia cases
* Incidence increases with age
* Doubles every 5.3 years
* Risk factors - hypercholesteremia, diabetes
mellitus, hypertension, and smoking
Lewy body dementia ___% of dementia cases
Lewy body dementia: ~5% of dementia cases
Parkinson disease dementia ___% of cases of
dementia
- Parkinson disease dementia 10% of cases of
dementia
Frontotemporal dementia ~___% of dementia
cases in patients older than ____ years of age
Frontotemporal dementia ~25% of dementia
cases in patients older than 65 years of age
Dementia-type diseases:
Cause _______ damage to various areas of your brain, causing _______ in
several areas of the brain to die
Dementia-type diseases:
Cause progressive damage to various areas of your brain, causing neurons in
several areas of the brain to die
Dementia-type diseases: (5)
- Alzheimer’s disease
- Frontotemporal dementia
- Chronic traumatic encephalopathy (CTE)
- Lewy body dementia
- Limbic predominant age-related TDP-43 encephalopathy
(LATE)
Alzheimer’s
Disease:
Premature aging of the brain Alzheimer disease is the most common cause of
dementia, ___ to ___% of all
cases of dementia.
Number is projected to double every ____ years and will increase to reach ____ million by 2050.
Characterized by a _______ decline in ______ and
_________ in personal daily activities.
Alzheimer’s
Disease:
Premature aging of the brain
Alzheimer disease is the most common cause of
dementia - 70 to 80% of all
cases of dementia.
Number is projected to double every 5 years and will
increase to reach 152 million by 2050.
Characterized by:
progressive decline in thinking and
independence in personal daily activities.
The National Institute on Aging—
Alzheimer’s Association
(updated the 1984 NINCDS-ADRDA criteria for
higher specificity and sensitivity)
- Positive lesions (due to __________),
characterized by the
_________ of __________ tangles,
_________ plaques, dystrophic neurites, neuropil threads, and other deposits found in the brains - Negative lesions (due to _____), that are characterized by large _______ due to a neural, neuropil, and synaptic loss
- Positive lesions (due to accumulation),
characterized by the
accumulation of neurofibrillary tangles,
amyloid plaques, dystrophic neurites, neuropil threads, and other deposits found in the brains - Negative lesions (due to losses), that are characterized by large atrophy due to a neural, neuropil, and synaptic loss
Alzheimer’s Disease Pathophysiology:
- Widespread _____ of the cortex
- Neuritic plaques composed of extracellular
______ ______ _______ deposition - Neurofibrillary tangles composed of
________ ____ proteins - Common to see signs of vascular ______
damage and _________ ______
Alzheimer’s Disease Pathophysiology:
- Widespread atrophy of the cortex
- Neuritic plaques composed of extracellular
amyloid beta protein deposition - Neurofibrillary tangles composed of
hyperphosphorylated tau proteins - Common to see signs of vascular ischemic
damage and hippocampal sclerosis
Alzheimer’s Disease:
Genetics:
1. All known mutations increase production of ____-______ proteins
2. ________ ____ patients – 3 copies of gene for
_______ precursor protein
3. Abnormality of gene controlling ___________
(cholesterol transporter) – accelerated deposition
of amyloid
4. Generation of anti-_______ ___________ in
Alzheimer disease appear to attenuate disease
process
Alzheimer’s Disease:
Genetics:
1. All known mutations increase production of beta-amyloid proteins
2. Trisomy 21 patients – 3 copies of gene for amyloid precursor protein
3. Abnormality of gene controlling apolipoprotein (cholesterol transporter) – accelerated deposition of amyloid
4. Generation of anti-amyloid antibodies in Alzheimer disease appear to attenuate disease process
Risk factors for Alzheimer’s (6):
Several risk factors
* increasing age
* genetic factors
* head injuries
* vascular diseases
* Infections
* environmental factors -
heavy metals, trace
metals, and others
Cerebrovascular disease caused by hypertension &
atherosclerosis may play role in dementia
_______, _________, & ________ increase risk
for developing dementia & progression of Alzheimer’s
Hypertension, diabetes, & hyperlipidemia increase risk for developing dementia & progression of Alzheimer’s
T/F
Lifestyle factors do not directly affect Alzheimer’s
disease pathology but can still contribute to a negative
outcome in individuals with Alzheimer’s disease.
False
Lifestyle factors do not directly affect Alzheimer’s
disease pathology but can still contribute to a positive
outcome in individuals with Alzheimer’s disease.
Promising pharmacological treatments for Alzheimer’s are poised at
advanced stages of clinical trials and include (3)
anti-amyloid β
anti-tau
anti-inflammatory strategies.
Clinical Phases of Alzheimer’s:
- Pre-clinical or the pre-symptomatic stage:
- mild _______ loss
- early pathological changes in ______ and ________
- no functional impairment in _____
- absence of clinical signs and symptoms
Clinical Phases of Alzheimer’s:
- Pre-clinical or the pre-symptomatic stage:
- mild memory loss
- early pathological changes in cortex and hippocampus
- no functional impairment in ADLs
- absence of clinical signs and symptoms
Clinical Phases of Alzheimer’s:
- Mild or early stage
* _______ start to appear in patients
* trouble in the daily life
* loss of ________ and _______
* disorientation of place and time
* change in _____
* development of ________
Clinical Phases of Alzheimer’s:
- Mild or early stage
* symptoms start to appear in patients
* trouble in the daily life
* loss of concentration and memory
* disorientation of place and time
* change in mood
* development of depression
Clinical Phases of Alzheimer’s:
- Moderate stage
* disease spreads to _______ ______ areas
* increased memory loss
* trouble _________
* loss of ______ control
* difficulty in ______, ______, and ______
Clinical Phases of Alzheimer’s:
- Moderate stage
* disease spreads to cerebral cortex areas
* increased memory loss
* trouble recognizing family and friends
* loss of impulse control
* difficulty in reading, writing, and speaking
Clinical Phases of Alzheimer’s:
- Severe AD or late-stage
* spread of the disease to the entire _____ area
* severe accumulation of _______ ______ and __________ tangles
* progressive functional and cognitive impairment - cannot recognize their family at all
* become ______
* difficulties in ______ and ______
* eventually leading to ____
Clinical Phases of Alzheimer’s:
- Severe AD or late-stage
* spread of the disease to the entire cortex area
* severe accumulation of neuritic plaques and neurofibrillary tangles
* progressive functional and cognitive impairment - cannot recognize their family at all
* become bedridden
* difficulties in swallowing and urination
* eventually leading to death
Frontotemporal Dementia
Neurodegenerative disorder is a spectrum of clinical syndromes
characterized by ______ degeneration involving the ______ and
_____ ________ lobes of the brain
Frontotemporal Dementia
Neurodegenerative disorder is a spectrum of clinical syndromes
characterized by neuronal degeneration involving the frontal and
anterior temporal lobes of the brain
Frontotemporal Dementia
Neurodegenerative disorde :
Clinical manifestations (5):
Etiology (2):
Clinical manifestations (5):
* behavior changes
* dietary changes
* loss of empathy
* Apathy
* Executive function
Etiology (2):
* Genetic
* Head trauma and thyroid disease linked with the development
Chronic Traumatic Encephalopathy
(CTE):
Neurodegenerative disease exhibiting a distinct pattern of neuropathological changes associated with _________ leading to increased risk of long-term memory and cognition issue.
Causes lesions at traumatic stress points leading to (3):
Chronic Traumatic Encephalopathy
(CTE):
Neurodegenerative disease exhibiting a distinct pattern of neuropathological changes associated with repetitive head trauma leading to increased risk of long-term memory and cognition issue.
Causes lesions at traumatic stress points leading to (3):
* axonal injury
* micro-hemorrhages
* subsequent loss of blood brain barrier integrity
Dementia Anesthesia Considerations:
Assessment of cognitive ability, capacity for decision making, & risk factors for POD
* Preoperative neuropsychiatric assessment –
establish baseline
Mini-Cog Assessment:
* Highly sensitive & specific for dementia
* Unbiased by variances in education & language
Criteria for Decision-making Capacity
1. Understanding treatment options
2. Appreciating & acknowledging medical condition & outcomes
3. Exhibiting reasoning & engaging in rational discussion of surgical treatment options
4. Clearly choosing a preferred treatment option
CNS changes result in increased sensitivity to anesthetic
agent
Changes in mood, memory, & motor function
* Increased risk for POD or further decrease in cognitive
disfunction
* Increased sensitivity d/t receptor downregulation
* Blood-brain barrier more permeable
* Decreased nerve conduction velocity
Pharmacological Interactions
Comprehensive medication list – multitude of anesthetic
implications
CNS changes result in increased sensitivity to anesthetic
agent
Frontotemporal Dementia
Neurodegenerative disorder:
Treatment (2 categories):
Frontotemporal Dementia
Neurodegenerative disorder:
Treatment (2 categories):
Non-pharmacologic:
social support services, physical therapy
& occupational therapy, speech therapy, cognitive behavior therapy, rehabilitation services, and caregivers’ education
Pharmacologic:
* Acetylcholinesterase inhibitors and N-methyl-D-aspartate inhibitors
* Selective serotonin reuptake inhibitors (SSRIs)
* Antipsychotics
* Dopaminergic antagonists
* Salsalate (tau acetylation inhibitor) and gosuraneb (anti-tau monoclonal antibodies)
Frontotemporal Dementia
Neurodegenerative disorder
Pharmacologic Treatment:
Frontotemporal Dementia
Neurodegenerative disorder
Pharmacologic:
* Acetylcholinesterase inhibitors and N-methyl-D-aspartate inhibitors
* Selective serotonin reuptake inhibitors (SSRIs)
* Antipsychotics
* Dopaminergic antagonists
* Salsalate (tau acetylation inhibitor) and gosuraneb (anti-tau monoclonal antibodies)
Chronic Traumatic Encephalopathy
(CTE):
Trigger an ________ cascade and a deposition of:
phosphorylated tau (p-tau) protein amyloid-beta (Aβ)
TDP-43
neurofibrillary triangles
neutrophil neurites
astrocytic tangles
neuronal loss and cerebral atrophy with white matter changes.
Symptoms (7):
Chronic Traumatic Encephalopathy
(CTE):
Trigger an inflammatory cascade and a deposition of:
*phosphorylated tau (p-tau) protein *amyloid-beta (Aβ)
*TDP-43
*neurofibrillary triangles
*neutrophil neurites
*astrocytic tangles
*neuronal loss and cerebral atrophy with white matter changes.
Symptoms (7):
* changes in behavior
* cognition and motor symptoms
* impulsivity, paranoia, rage behaviors,
* headaches
* memory deficits, impaired attention
* dysphagia, dysarthria,
* coordination problems
- Most prevalent demyelinating disorders
- Combinations of inflammation, demyelination, and axonal
damage in the central nervous system - Loss of myelin covering the axons is followed by formation of
demyelinated plaques. - Immune mediated inflammatory disease
Multiple Sclerosis (MS)
Common demyelinating diseases that
affect your central nervous system
(brain and spinal cord) include (6):
- Multiple sclerosis (MS)
- Neuromyelitis optica spectrum disorder (NMOSD)
- Transverse myelitis (TM)
- Acute disseminated
encephalomyelitis (ADEM) - Progressive multifocal
leukoencephalopathy (PML). - Central pontine myelinolysis
(osmotic demyelination
syndrome).
Multiple Sclerosis (MS) attacks what anatomical structures (3):
- myelin
- oligodendrocytes (myelin producing cells)
- underlying nerve fibers
Multiple
Sclerosis (MS) Symptoms (11):
a) Fatigue
b) Tingling
c) Numbness
d) Muscle weakness
e) Ataxia
f) Vertigo
g) Tremor
h) Spasticity
i) Bowel & bladder disfunction
j) Pain
k) Heat intolerance
Multiple Sclerosis:
Contribute to ________ & _______
* Affects young adults between ages ___-___ years of age
* ______ affected two times more than ___
* Significant disability results in __ - __ years
* Characterized by periods of ______ & _______
Multiple Sclerosis:
Contribute to demyelination & neurodegeneration
* Affects young adults between ages 20-40 years of age
* Females affected two times more than males
* Significant disability in 20 -25 years
* Characterized by periods of relapse & remission
Multiple
Sclerosis (MS) Diagnosis (3):
a) MRI
b) Elevated IgG in the cerebrospinal fluid
c) Decreased conduction velocity on evoke potential studies
Treatment of Multiple
Sclerosis (MS):
__________ agents directed toward reducing
formation of new lesions & decreasing incidence of relapse
Treatment of Multiple
Sclerosis (MS):
Immunomodulatory agents directed toward reducing
formation of new lesions & decreasing incidence of relapse
Multiple Sclerosis (MS) Risk Factors (6):
Risk Factors:
a) female sex
b) exposure to Epstein-Barr or varicella zoster viruses
c) diabetes mellitus type 1
d) inflammatory bowel disease
e) low vitamin D levels
f) smoking
Multiple Sclerosis Anesthesia Considerations:
- Consider the impact of surgical ______ on the natural ______ of the disease
- Possible signs & symptoms of MS will be ______ _______
- infection and fever: increased body temperature results in complete _____ of _____ in __________ nerves
Multiple Sclerosis Anesthesia Considerations:
- Consider the impact of surgical stress on the natural progression of the disease
- Possible signs & symptoms of MS will be exacerbated postoperatively
- infection and fever: increased body temperature results in complete block of conduction in demyelinated nerves
Multiple Sclerosis Anesthesia Considerations:
T/F
There is NO evidence to support the use of one inhaled or injected anesthetic drug over another
Multiple Sclerosis Anesthesia Considerations:
TRUE
There is NO evidence to support the use of one inhaled or injected anesthetic drug over another
Multiple Sclerosis Anesthesia Considerations:
Muscle relaxants
- Avoid use of _______ in patients with _____ weakness
use of _______ can result in exaggerated ________ release and should be avoided
Multiple Sclerosis Anesthesia Considerations:
Avoid use of succinylcholine in patients with motor weakness
use of succinylcholine can result in exaggerated potassium release and should be avoided
Multiple Sclerosis Anesthesia Considerations:
Muscle Relaxants
- Avoid use of succinylcholine in patients with ______ weakness
- _______ responses to the paralyzing effects of _________ muscle relaxants
- coexisting skeletal muscle ______ and decreased skeletal muscle _____
- _______ to the effects of nondepolarizing muscle relaxants has been observed
- reflects the proliferation of extrajunctional ________ receptors characteristic of ______ motor neuron lesions
Multiple Sclerosis Anesthesia Considerations:
Muscle Relaxants
- Avoid use of succinylcholine in patients with motor weakness
- Prolonged responses to the paralyzing effects of nondepolarizing muscle relaxants
- coexisting skeletal muscle weakness and decreased skeletal muscle mass
- Resistance to the effects of nondepolarizing muscle relaxants has been observed
- reflects the proliferation of extrajunctional cholinergic receptors characteristic of upper motor neuron lesions
Multiple Sclerosis Anesthesia Considerations:
- Corticosteroid supplementation – consideration in patients on long-term corticosteroids
???
Multiple Sclerosis Anesthesia Considerations:
Regional anesthetic techniques - changing and unpredictable neurologic presentation during the perioperative period must be appreciated
- hypothesized that intrathecal administration of _____ anesthetics promoted demyelination in the spinal cord
- ______ regions of the spinal cord may be _____ susceptible to the ______ effects of ______ anesthetics
- _____ and _____ analgesia & anesthesia have been used safely
Multiple Sclerosis Anesthesia Considerations:
Regional anesthetic techniques - changing and unpredictable neurologic presentation during the perioperative period must be appreciated
- hypothesized that intrathecal administration of local anesthetics promoted demyelination in the spinal cord
- Demyelinated regions of the spinal cord may be more susceptible to the neurotoxic effects of local anesthetics
- epidural and spinal analgesia & anesthesia have been used safely
GBS Progression:
________ response triggers an _________ response to peripheral nerves & spinal root
Symptoms progress over several days to reach peak at ___ to ___ weeks
- max loss of function ___ hours
- 4 weeks ______ _______ to limit of symptoms
- Recovery protracted for months to years – depend on extent of ______ injury
GBS Progression:
Autoimmune response triggers an autoimmune response to peripheral nerves & spinal root
Symptoms progress over several days to reach peak at 2 to 4 weeks
* max loss of function 72 hours
* 4 weeks most progressed to limit of symptoms
* Recovery protracted for months to years – depend on extent of nerve injury
Most common variant of GBS - Acute Inflammatory demyelinating polyneuropathy (AIDP)
Manifest as:
* _______ _______ muscle weakness that progressively leads to severe flaccid _____ &
respiratory _____
- Sensory & motor features depend on _____
- _____ of patients have history of ____ or _____ infection
- Severe limb weakness
- Related to ______ antibody response against GMI & GDI a gangliosides
MFS - Anti-GQ1b antibodies
Most common variant of GBS - Acute Inflammatory demyelinating polyneuropathy (AIDP)
Manifest as:
- symmetric ascending muscle weakness that progressively leads to severe flaccid paralysis &
respiratory failure - Sensory & motor features depend on subtype
- Half of patients have history of bacterial or viral infection
- Severe limb weakness
- Related to autoimmune antibody response against GMI & GDI a gangliosides
MFS - Anti-GQ1b antibodies
- Symptoms affect cranial nerves resulting in clinical triad: ophthalmoplegia, ataxia, & areflexia
Common demyelinating diseases that
affect your peripheral nervous system
include (3):
- Guillain-Barré
syndrome (GBS) - Charcot-Marie-Tooth
disease (CMT) - Chronic inflammatory
demyelinating
polyneuropathy (CIDP)
Guillain-Barré
syndrome (GBS):
Occurring at a rate of 1-2 cases/100,000 persons per
year worldwide
* Increases with ____
* More prevalent in ___
Guillain-Barré
syndrome (GBS)
Occurring at a rate of 1-2 cases/100,000 persons per
year worldwide
* Increases with age
* More prevalent in men
Most common variant of GBS
Acute Inflammatory demyelinating polyneuropathy (AIDP)
GBS Symptoms:
affect ______ nerves resulting in clinical triad:
GBS Symptoms:
affect cranial nerves resulting in clinical triad:
*ophthalmoplegia
*ataxia
*areflexia
- Progressive dementia combined with choreoathetosis
- Marked atrophy of the caudate nucleus - lesser degree putamen & globus pallidus
- Abnormal movements caused by the loss of most of the cell bodies:
- GABA-secreting neurons in the caudate nucleus & putamen
- Acetylcholine-secreting neurons in many parts of the brain
- Loss of inhibition allows spontaneous outbursts of globus pallidus & substantia nigra activity that cause the
distortional movements
Treatment - Supportive - directed at decreasing the choreiform movement
- Haloperidol and other butyrophenones - control the chorea and emotional lability
- Drugs that interfere with the neurotransmitter effects of dopamine
- antagonizing dopamine (risperidone, olanzapine)
- depleting dopamine stores (tetrabenazine, deutetrabenazine)
Anesthesia Considerations - Preoperative sedation - butyrophenones such as droperidol or haloperidol - controlling choreiform movements
- Increased likelihood of pulmonary aspiration
- Acceptable anesthesia techniques include
- Nitrous oxide & inhalational anesthetics
- Propofol & succinylcholine
- Spinal anesthesia
?????